Trial Profile
An Open Label, Single Arm, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (L-MOCA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms L-MOCA
- Sponsors AstraZeneca
- 31 Aug 2022 Planned End Date changed from 21 Dec 2021 to 1 Oct 2023.
- 31 Aug 2022 Planned primary completion date changed from 21 Dec 2021 to 1 Oct 2023.
- 07 Jun 2022 Results of an exploratory assessed HRD and PD-L1 status presented at the 58th Annual Meeting of the American Society of Clinical Oncology